Compare Endeavour Silver Corp (EXK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Viatris Inc — how do they compare? Endeavour Silver Corp trades at $8.83 (market cap $2.54B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 7.9× Endeavour Silver Corp's market cap, and Viatris Inc pays a 2.75% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Viatris Inc for 57 Days on average.
| EXK | VTRS | |
|---|---|---|
Market Cap | $2.54B | $20.03B |
Volume | 7,077,330 | 14,109,977 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $18.27 |
52-Week Low | $7.07 | $9.74 |
Typical Hold Time | 25 Days | 57 Days |
Enterprise Value | $2.54B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.32, down 4.04% today, amid a bearish technical signal. The company reported mixed Q2 2026 earnings, matching estimates with $0.15 EPS, but showed strong revenue growth and improved profitability in 2026. Recent news highlights operational progress at Terronera and Kolpa mines, though temporary disruptions occurred. Analyst consensus remains strongly bullish with a $10.50 price target.
Outlook is cautiously optimistic driven by production growth and favorable metal prices, but risks include operational disruptions and high valuation multiples. The stock offers potential upside from current levels if execution continues, but volatility from commodity prices and mine-specific issues persists.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
